Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

OBJECTIVE: Fabry disease results from alpha-gala-ctosidase A deficiency and is characterized by the lysosomal accumulation of globotriaosylceramide. Globotriaosylceramide storage predominantly affects endothelial cells, altering vascular wall morphology and vasomotor function. Our objective was to i...

書誌詳細
主要な著者:	Heare, T, Alp, N, Priestman, D, Kulkarni, AB, Qasba, P, Butters, T, Dwek, R, Clarke, K, Channon, K, Platt, F
フォーマット:	Journal article
言語:	English
出版事項:	2007

類似資料

N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
著者:: Priestman, D, 等
出版事項: (2008)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
著者:: Jeyakumar, M, 等
出版事項: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
著者:: Andersson, U, 等
出版事項: (2000)

Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
著者:: Walden, C, 等
出版事項: (2006)

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
著者:: Fischer, P, 等
出版事項: (1995)

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
著者:: Cox, T, 等
出版事項: (2000)

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
著者:: Elstein, D, 等
出版事項: (2004)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
著者:: Platt, F, 等
出版事項: (2003)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
著者:: Ranes, M, 等
出版事項: (2001)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
著者:: Denny, C, 等
出版事項: (2010)

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.
著者:: Pollock, S, 等
出版事項: (2008)

Imino sugar therapy for type 1 Gaucher disease.
著者:: Priestman, D, 等
出版事項: (2000)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice.
著者:: Garner, B, 等
出版事項: (2002)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
著者:: Priestman, D, 等
出版事項: (2008)

Increased endothelial tetrahydrobiopterin levels by GTPCH over expression in transgenic mice prevents diabetic endothelial dysfunction
著者:: Alp, N, 等
出版事項: (2003)

Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.
著者:: Speak, A, 等
出版事項: (2007)

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
著者:: Jefferson Loso, 等
出版事項: (2018-08-01)

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation
著者:: Solvey Pollmann, 等
出版事項: (2021-11-01)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice
著者:: Brett Garner, 等
出版事項: (2002-02-01)

Effects of N-butyldeoxynojirimycin and the Lec3.2.8.1 mutant phenotype on N-glycan processing in Chinese hamster ovary cells: application to glycoprotein crystallization.
著者:: Butters, T, 等
出版事項: (1999)

An MRI technique for the quantification of atherosclerotic lesions in the ApoE knockout mouse
著者:: Grieve, S, 等
出版事項: (2002)

Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
著者:: Cosimo A. Stamerra, 等
出版事項: (2021-01-01)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
著者:: Pelled, D, 等
出版事項: (2003)

High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta.
著者:: Ivana Nemeckova, 等
出版事項: (2015-01-01)

Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation.
著者:: Cai, S, 等
出版事項: (2005)

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence
著者:: Welford, R, 等
出版事項: (2017)

Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.
著者:: Branza-Nichita, N, 等
出版事項: (2001)

Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice.
著者:: Alp, N, 等
出版事項: (2004)

N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV
著者:: Lauren C. Boudewyn, 等
出版事項: (2017-09-01)

Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
著者:: Mehdi Namdar, 等
出版事項: (2012-01-01)

Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease.
著者:: Alp, N, 等
出版事項: (2004)

Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta
著者:: Ajay, M., 等
出版事項: (2005)

Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
著者:: Fang Han, 等
出版事項: (2015-02-01)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
著者:: Butters, T, 等
出版事項: (2005)

Therapeutic applications of imino sugars in lysosomal storage disorders.
著者:: Butters, T, 等
出版事項: (2003)

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
著者:: Butters, T, 等
出版事項: (2005)

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
著者:: Butters, T, 等
出版事項: (2003)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
著者:: Butters, T, 等
出版事項: (2000)

The apo E gene knockout mouse as a model to study the potential atherogenic properties of glycosphingolipids
著者:: Garner, B, 等
出版事項: (2003)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
出版事項: (2012-01-01)